BIOMAT Database Logo BIOMAT Database Logo

Evaluation of prognostic factors for 233 patients with recurrent advanced breast cancer. 1991

K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
Cancer Institute Hospital, Department of Clinical Oncology, Tokyo.

We analyzed possible prognostic factors in 233 patients with recurrent advanced breast cancer treated primarily by adriamycin, cyclophosphamide and ftorafur (ACF) therapy and ACF modifications. The patients were in the Cancer Institute Hospital from 1977 to 1986, and were followed-up until 1989. In terms of chemotherapeutic response, complete and partial responses were observed in 31 (13%) and 100 (43%) patients, respectively. The overall median survival from the beginning of chemotherapy was 20.3 months. The factors evaluated were response to chemotherapy, performance status (PS), age, disease-free interval (DFI), menopausal status, number of metastatic sites (step classification), presence or absence of liver metastasis, presence or absence of malignant effusion, and presence or absence of prior radiotherapy. Out of the nine factors, response to chemotherapy, PS, age, DFI and liver metastasis were significant factors affecting survival in univariate analysis, and multivariate analysis of these five factors revealed the survival to be markedly affected by response to chemotherapy (P less than 0.00001), PS (P = 0.00001) and DFI (P less than 0.00001).

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005260 Female Females
D005641 Tegafur Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms. 1-(2-Tetrahydrofuryl)-5-fluorouracil,1-(Tetrahydro-2-furanyl)-5-fluorouracil,5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione,FT-207,FT207,Florafur,Fluorofur,Ftorafur,Futraful,N1-(2'-Tetrahydrofuryl)-5-fluorouracil,Sunfural S,Uftoral,Utefos,FT 207
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
Prognostic Factors for Advanced/Recurrent Breast Cancer Treated With Immune-cell Therapy.
August 2021, Anticancer research,
K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
Assessment of prognostic factors for locally advanced breast cancer.
May 2012, Journal of the Indian Medical Association,
K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
[Pharyngolaryngectomy for advanced and recurrent cancer: prognostic factors and complications].
January 2004, Revue de laryngologie - otologie - rhinologie,
K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
Evaluation of serum tumor markers in patients with advanced or recurrent breast cancer.
January 1995, Breast cancer research and treatment,
K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
Prognostic factors in patients with advanced and recurrent colorectal cancer receiving last-line chemotherapy.
February 2018, Die Pharmazie,
K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
Breast cancer prognostic factors: evaluation guidelines.
February 1991, Journal of the National Cancer Institute,
K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
Prognostic factors in patients with advanced prostate cancer.
May 1989, Urology,
K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.
January 2024, BMC cancer,
K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
[Evaluation of prognostic factors in breast cancer].
January 1984, Bulletin du cancer,
K Inoue, and M Ogawa, and N Horikoshi, and K Aiba, and T Mukaiyama, and N Mizunuma, and S Itami, and A Hirano, and A Matsuoka, and T Matsumura
[EVALUATION OF PROGNOSTIC FACTORS IN BREAST CANCER].
January 1965, Voprosy onkologii,
Copied contents to your clipboard!